CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
11 hedge funds and large institutions have $799K invested in CERo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
38% more funds holding
Funds holding: 8 → 11 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
34.79% less ownership
Funds ownership: 47.82% → 13.02% (-35%)
66% less capital invested
Capital invested by funds: $2.38M → $799K (-$1.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$75.4K |
| 2 |
Citigroup
New York
|
+$7.12K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.52K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
-$728K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$19.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Parallel Advisors
San Francisco,
California
| $616K | -$728K | -99,000 | -45% |
|
|
AVM
2
Arch Venture Management
Chicago,
Illinois
| $114K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $52.1K | +$75.4K | +10,244 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6.61K | +$4.52K | +615 | +90% |
|
|
FIA
5
FNY Investment Advisers
New York
| $5K | – | – | – |
|
|
6
Citigroup
New York
| $4.93K | +$7.12K | +968 | New |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $92 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $30 | -$19.3K | -2,619 | -100% |
|
9
Jones Financial Companies
Des Peres,
Missouri
| $16 | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| $15 | +$7 | +1 | +50% |
|
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$7 | +1 | New |
|
CERO Hedge Fund Activity: Q3 2025 in Review
11 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q3 2025, worth a combined $799K — down 66% from $2.38M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CERO positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $75.4K. The largest seller was Parallel Advisors, cutting an estimated $728K.
- 11 institutional investors held CERo Therapeutics (CERO) as of Q3 2025, up from 8 in Q2 2025.
- Funds reported $799K of CERo Therapeutics stock for Q3 2025, down 66% quarter-over-quarter.
- 3 funds opened new CERo Therapeutics positions in Q3 2025 and 0 closed out, a net change of +3 holders.
- The largest CERo Therapeutics buyer in Q3 2025 was Susquehanna International Group, an estimated $75.4K added.
- The largest CERo Therapeutics seller in Q3 2025 was Parallel Advisors, an estimated $728K sold.
Based on aggregated 13F filings for Q3 2025.